mizagliflozin (VGX-3235) / Vogenx 
Welcome,         Profile    Billing    Logout  
 4 Diseases   1 Trial   1 Trial   27 News 
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Enrollment closed, Trial completion date, Trial primary completion date, Adverse events:  Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions (clinicaltrials.gov) -  Mar 21, 2024   
    P2,  N=15, Active, not recruiting, 
    Trial completion date: Aug 2024 --> May 2025 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> May 2024
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Biomarker, Journal:  SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast. (Pubmed Central) -  Jul 13, 2023   
    This is the first study demonstrating that SGLT1 inhibitors suppressed breast carcinoma cell proliferation. These results indicated that SGLT1 inhibitors could be used as therapeutic agents for breast cancer patients with aggressive biological behaviors.
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Trial completion date, Trial initiation date, Trial primary completion date, Adverse events:  Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions (clinicaltrials.gov) -  May 12, 2023   
    P2,  N=15, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2023 --> Dec 2023 | Initiation date: Mar 2023 --> Jun 2023 | Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Phloretin Improves Ultrafiltration and Reduces Glucose Absorption During Peritoneal Dialysis in Rats (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1368;    
    Methods Here we tested a selective blocker of sodium glucose co-transporter 1, mizagliflozin, as well as phloretin, a non-selective blocker of facilitative glucose channels in an experimental model of peritoneal dialysis in anesthetized Sprague-Dawley rats...95% confidence intervals of phloretin effect on Isocratic, Isovolumetric and Three-pore model glucose diffusion capacity (MTAC), Three-pore model urea MTAC, ultrafiltration-rate (UF-rate) and sodium removal compared to sham group. Interval marker represent the median of the difference.
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Trial completion, Trial primary completion date:  Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC) (clinicaltrials.gov) -  Apr 18, 2016   
    P2,  N=0, Completed, 
    Interval marker represent the median of the difference. Recruiting --> Completed | Trial primary completion date: Oct 2015 --> May 2015
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Trial completion, Trial primary completion date:  Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC) (clinicaltrials.gov) -  Apr 18, 2016   
    P2,  N=0, Completed, 
    Recruiting --> Completed | Trial primary completion date: Oct 2015 --> May 2015 Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Trial completion, Trial primary completion date:  A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation (clinicaltrials.gov) -  Nov 13, 2014   
    P2,  N=0, Completed, 
    Recruiting --> Completed | Trial primary completion date: Oct 2015 --> May 2015 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014
  • ||||||||||  mizagliflozin (VGX-3235) / Vogenx
    Trial completion, Trial primary completion date:  A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation (clinicaltrials.gov) -  Nov 13, 2014   
    P2,  N=0, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014